Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 10, 2019European Journal of CancerOpen Access

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGuillaume MansonHôpital PontchaillouJMJean-Baptiste MéarCentre Hospitalier Universitaire de RennesCHCharles HerbauxCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Manson et al. (2019) studied this question.

synapsesocial.com/papers/6aa698227b142bbe3664d4efhttps://doi.org/10.1016/j.ejca.2019.04.006
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas1999 · 3,492 citations
  2. 2Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant2013 · 141 citations
  3. 3High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma2013 · 97 citations
  4. 4Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome2008 · 120 citations
  5. 5Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma2017 · 241 citations